دورية أكاديمية
Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.
| العنوان: | Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets. |
|---|---|
| المؤلفون: | Friedman CF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medicine, New York, New York., Ravichandran V; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Miller K; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Vanderbilt C; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Zhou Q; Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Iasonos A; Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Vivek M; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Mishra P; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Leitao MM Jr; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of OB/GYN, Weill Cornell Medical College, New York, New York., Broach V; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of OB/GYN, Weill Cornell Medical College, New York, New York., Sonoda Y; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of OB/GYN, Weill Cornell Medical College, New York, New York., Kyi C; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medicine, New York, New York., Zamarin D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medicine, New York, New York., O'Cearbhaill RE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medicine, New York, New York., Konner J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medicine, New York, New York., Berger MF; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Weigelt B; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Momeni Boroujeni A; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Park KJ; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Aghajanian C; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medicine, New York, New York., Solit DB; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medicine, New York, New York.; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Donoghue MTA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Nov 14; Vol. 29 (22), pp. 4660-4668. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Denville, NJ : The Association, c1995- |
| مواضيع طبية MeSH: | Uterine Cervical Neoplasms*/drug therapy , Uterine Cervical Neoplasms*/genetics, Female ; Humans ; Prospective Studies ; Genomics ; Mutation ; Microsatellite Instability ; Biomarkers, Tumor/genetics ; High-Throughput Nucleotide Sequencing/methods |
| مستخلص: | Purpose: Tumor genomic profiling is increasingly used to guide treatment strategy in patients with cancer. We integrated tumor genomic, clinical demographic, and treatment response data to assess how prospective tumor-normal sequencing impacted treatment selection in patients with cervical cancer. Experimental Design: Cervical cancers were prospectively analyzed using the MSK-IMPACT (Memorial Sloan Kettering Cancer Center - Integrated Mutation Profiling of Actionable Cancer Targets) next-generation sequencing panel. Clinical data, including histology, stage at diagnosis, treatment history, clinical trial enrollment and outcomes, date of last follow-up, and survival status were obtained from medical records. Results: A total of 177 patients with cervical cancer (squamous, 69; endocervical adenocarcinoma, 50; gastric type, 22; adenosquamous, 21; and other, 15) underwent MSK-IMPACT testing. The most prevalent genomic alterations were somatic mutations or amplifications in PIK3CA (25%), ERBB2 (12%), KMT2C (10%), and KMT2D (9%). Furthermore, 13% of patients had high tumor mutational burden (TMB >10 mut/Mb), 3 of which were also microsatellite instability-high (MSI-H). Thirty-seven percent of cases had at least one potentially actionable alteration designated as a level 3B mutational event according to the FDA-recognized OncoKB tumor mutation database and treatment classification system. A total of 30 patients (17%) were enrolled on a therapeutic clinical trial, including 18 (10%) who were matched with a study based on their MSK-IMPACT results. Twenty patients (11%) participated in an immune checkpoint inhibition study for metastatic disease; 2 remain progression free at >5 years follow-up. Conclusions: Tumor genomic profiling can facilitate the selection of targeted/immunotherapies, as well as clinical trial enrollment, for patients with cervical cancer. (©2023 The Authors; Published by the American Association for Cancer Research.) |
| References: | J Immunother Cancer. 2020 Dec;8(2):. (PMID: 33323462) Cancer Discov. 2017 Aug;7(8):818-831. (PMID: 28572459) J Mol Diagn. 2022 May;24(5):515-528. (PMID: 35331965) Lancet Oncol. 2020 Oct;21(10):1353-1365. (PMID: 32919526) Cancer Gene Ther. 2022 Jul;29(7):875-878. (PMID: 34471232) Am J Surg Pathol. 2017 May;41(5):607-615. (PMID: 28403015) Br J Cancer. 2020 Dec;123(12):1790-1795. (PMID: 33020595) Mol Diagn Ther. 2022 May;26(3):301-308. (PMID: 35380358) J Clin Oncol. 2019 Jun 10;37(17):1470-1478. (PMID: 30943124) J Natl Cancer Inst. 1995 Jun 7;87(11):796-802. (PMID: 7791229) Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774) Int J Cancer. 1998 Feb 9;75(4):536-45. (PMID: 9466653) N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255) J Clin Oncol. 2016 Jun 20;34(18):2141-7. (PMID: 27022117) Mod Pathol. 2021 Mar;34(3):637-646. (PMID: 32641744) JCO Precis Oncol. 2017 Jul;2017:. (PMID: 28890946) CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204) N Engl J Med. 2021 Nov 11;385(20):1856-1867. (PMID: 34534429) Mod Pathol. 2021 Jun;34(6):1213-1225. (PMID: 33318584) Nat Med. 2017 Jun;23(6):703-713. (PMID: 28481359) Nature. 2017 Mar 16;543(7645):378-384. (PMID: 28112728) N Engl J Med. 2022 Jan 20;386(3):241-251. (PMID: 34534430) N Engl J Med. 2022 Mar 24;386(12):1143-1154. (PMID: 35320644) Arch Pathol Lab Med. 2012 Oct;136(10):1266-97. (PMID: 22742517) Expert Rev Mol Diagn. 2017 Apr;17(4):379-391. (PMID: 28277144) Histopathology. 2020 Jan;76(1):151-156. (PMID: 31846528) JCO Precis Oncol. 2017;2017:. (PMID: 30211344) Nat Genet. 2020 Aug;52(8):800-810. (PMID: 32747824) Gynecol Oncol. 2020 Oct;159(1):150-156. (PMID: 32723675) J Clin Oncol. 2019 Oct 20;37(30):2759-2768. (PMID: 31408414) Nature. 2014 Feb 20;506(7488):371-5. (PMID: 24390348) Best Pract Res Clin Obstet Gynaecol. 2005 Aug;19(4):469-83. (PMID: 16150388) J Clin Oncol. 2004 Aug 1;22(15):3113-9. (PMID: 15284262) Int J Cancer. 2000 May 1;86(3):429-35. (PMID: 10760834) Immunotargets Ther. 2020 Oct 07;9:167-200. (PMID: 33117742) Sci Rep. 2021 Sep 28;11(1):19261. (PMID: 34584128) Am J Surg Pathol. 2015 Nov;39(11):1449-57. (PMID: 26457350) Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308) N Engl J Med. 2020 Jun 18;382(25):2419-2430. (PMID: 32469182) BMC Cancer. 2007 Aug 23;7:164. (PMID: 17718897) J Clin Oncol. 2019 Nov 1;37(31):2825-2834. (PMID: 31487218) |
| معلومات مُعتمدة: | P30 CA008748 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20230829 Date Completed: 20231115 Latest Revision: 20240314 |
| رمز التحديث: | 20240315 |
| مُعرف محوري في PubMed: | PMC10644000 |
| DOI: | 10.1158/1078-0432.CCR-23-1078 |
| PMID: | 37643132 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-3265 |
|---|---|
| DOI: | 10.1158/1078-0432.CCR-23-1078 |